WATCH: How could AI patentability in Europe inform risk management discussions for investment in digital technology innovation within pharma?

Patents are key to ensuring continued investment in pharma R&D

What are the unique patent considerations for pharma/biotech patents and AI patents in Europe?

What are the potential effects of cross-over tech on patent grant rate?

Are there any potential future implications of AI on patentability in Europe?

How might this affect risk profile for investment in digital technology innovation within pharma?